
Senior Director, Clinical Science, Oncology Early Development (Hybrid)
Merck
Summary
The Senior Director, Clinical Science, Oncology Early Development provides strategic Clinical Science leadership for novel assets from candidate transition through first-in-human development and clinical proof-of-concept. Reporting to the Executive Director, this role applies deep expertise in early-phase oncology, translational medicine, biomarker strategy, and first-in-human trial design to shape development plans and enable data-driven decision-making across the early oncology portfolio.
Job description
Key Responsibilities
- Provide strategic Clinical Science leadership across Oncology Early Development, including multiple studies, programs, and assets.
- Contribute to early clinical development strategy from candidate transition through first-in-human evaluation and clinical proof-of-concept.
- Integrate disease biology, mechanism of action, translational evidence, competitive landscape, and emerging data to identify development opportunities, risks, and key decision points.
- Establish and advance consistent Clinical Science standards for early development planning, medical data review, dose-escalation meetings, data interpretation, and key deliverables.
- Guide interpretation of clinical data across studies, cohorts, and assets.
- Contribute scientific perspective to protocol development, amendments, study design, endpoint selection, eligibility criteria, and biomarker strategy.
- Contribute Clinical Science expertise to portfolio discussions, governance reviews, and senior leadership meetings.
- Provide direct management for Directors, Principal Scientists, and Clinical Scientists.
- Support development of Clinical Science talent through coaching, mentoring, and feedback.
- Partner closely with Clinical Operations, Regulatory Affairs, Biostatistics, Data Management, Drug Safety and Pharmacovigilance, Translational Medicine, and Medical Affairs.
- Ensure Clinical Science activities comply with regulatory requirements, company policies, and established procedures.
Education
Advanced scientific or healthcare degree required (e.g., PhD, PharmD), or equivalent, with 8+ years of pharmaceutical, clinical drug development, and/or medical field experience preferred. Master's degree, preferably in life sciences, with 12+ years of experience. Bachelor's degree, preferably in life sciences, with 15+ years of experience.
Experience
- Significant experience in Clinical Development, Clinical Science, clinical drug development, or a related function within the pharmaceutical or biotechnology industry, with substantial responsibility in early-phase development.
- Demonstrated leadership of first-in-human and early-phase oncology studies, including dose escalation, dose optimization, cohort expansion, and proof-of-concept planning.
- Deep understanding of oncology disease biology, novel mechanisms and modalities, translational medicine, biomarker-driven development, PK/PD, and safety and tolerability assessment.
- Strong understanding of clinical trial design, clinical development strategy, clinical data review, and interpretation of oncology data.
- Experience contributing to protocols, regulatory submissions, safety reviews, health authority interactions, governance discussions, and cross-program planning.
- Experience working effectively within cross-functional teams in a matrixed environment.
- Demonstrated ability to integrate information across studies and programs to support scientific and business decision-making.
- Excellent communication, influence, and executive presentation skills.
- Demonstrated people leadership experience, including management, coaching, and development of scientific staff.
Requirements
- Advanced scientific or healthcare degree required (e.g., PhD, PharmD), or equivalent
- 8+ years of pharmaceutical, clinical drug development, and/or medical field experience preferred (advanced degree)
- Master's degree with 12+ years of pharmaceutical, clinical drug development, and/or medical field experience
- Bachelor's degree with 15+ years of pharmaceutical, clinical drug development, and/or medical field experience
- Significant experience in Clinical Development, Clinical Science, clinical drug development, or related function in pharmaceutical or biotechnology industry
- Substantial responsibility in early-phase development
- Demonstrated leadership of first-in-human and early-phase oncology studies
- Experience with dose escalation, dose optimization, cohort expansion, and proof-of-concept planning
- Deep understanding of oncology disease biology, novel mechanisms and modalities, translational medicine, biomarker-driven development, PK/PD, and safety assessment
- Strong understanding of clinical trial design, clinical development strategy, clinical data review, and interpretation of oncology data
- Experience contributing to protocols, regulatory submissions, safety reviews, health authority interactions, governance discussions, and cross-program planning
- Experience working effectively within cross-functional teams in a matrixed environment
- Demonstrated ability to integrate information across studies and programs
- Excellent communication, influence, and executive presentation skills
- Demonstrated people leadership experience, including management, coaching, and development of scientific staff
Benefits
- Medical, Dental & Vision
- 401(k) Matching
- Retirement Benefits
- Paid Holidays
- Vacation
- Compassionate & Sick Days
- Annual Bonus
- Long-Term Incentive
Company overview
Merck & Co., Inc., known as Merck in the United States and Canada and MSD (Merck Sharp & Dohme) internationally, is a premier American multinational pharmaceutical company headquartered in Rahway, New Jersey. Founded in 1891 as the U.S. subsidiary of the German Merck Group, the company became independent following World War I and has since grown into one of the world's largest biomedical companies, ranking fourth globally by revenue. Merck operates across three core business segments: pharmaceuticals, vaccines, and animal health products. The company is renowned for its groundbreaking research and development, having brought numerous life-saving medicines to market including Keytruda (pembrolizumab), a leading immunotherapy for cancer treatment that generated $29.5 billion in 2024 revenue, and Gardasil, a revolutionary HPV vaccine. With approximately 75,000 employees worldwide, Merck maintains a robust pipeline of innovative therapies focused on oncology, vaccines, hospital acute care, cardiology, neuroscience, virology, immunology, and diabetes. The company invests heavily in R&D, spending $17.9 billion in 2024 alone, demonstrating its commitment to advancing scientific discovery. Merck's legacy spans over 130 years of bringing hope to humanity through important medicines and vaccines, operating with a purpose to use leading-edge science to save and improve lives globally while fostering an inclusive workforce and responsible business practices.